TD Cowen on Oruka Therapeutics (ORKA): '39-49% Or Higher PASI 100 Should Unlock Multi-Billion Sales'
TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Oruka Therapeutics (NASDAQ: ORKA).The analyst commented: "ORKA-001 Preview: 39-49 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)